{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ALT803&page=2",
    "query": {
      "intervention": "ALT803",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ALT803&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T17:55:26.324Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03003728",
      "title": "2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Autologous Stem Cell Transplant (ASCT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Expanded Natural Killer (ENK) Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALT-803",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-11-01",
      "completion_date": "2020-07-08",
      "has_results": false,
      "last_update_posted_date": "2020-07-10",
      "last_synced_at": "2026-09-11T17:55:26.324Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03003728"
    },
    {
      "nct_id": "NCT02138734",
      "title": "A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "BCG (50mg/instillation) + N-803 (400 μg/instillation)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG (50mg/instillation)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 369,
      "start_date": "2014-07-21",
      "completion_date": "2039-03-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-09-11T17:55:26.324Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138734"
    },
    {
      "nct_id": "NCT02465957",
      "title": "QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IIIB Merkel Cell Carcinoma",
        "Stage IV Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "aNK (NK-92)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aNK (NK-92) + N-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2015-09-24",
      "completion_date": "2018-03-19",
      "has_results": true,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-09-11T17:55:26.324Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Pittsburgh, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465957"
    },
    {
      "nct_id": "NCT07686380",
      "title": "IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Prostate Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "N-803",
          "type": "DRUG"
        },
        {
          "name": "ETBX-71 Vaccine",
          "type": "DRUG"
        },
        {
          "name": "18F-DCFPyL",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 65,
      "start_date": "2026-09-16",
      "completion_date": "2029-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-11T17:55:26.324Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07686380"
    },
    {
      "nct_id": "NCT06161545",
      "title": "Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage II Squamous Cell Carcinoma of the Head and Neck",
        "Stage III Squamous Cell Carcinoma of the Head and Neck",
        "Stage IV Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "PD-L1 t-haNK cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-24",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-11T17:55:26.324Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06161545"
    },
    {
      "nct_id": "NCT03387085",
      "title": "QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Aldoxorubicin HCl",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-051",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-061",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-4000",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-6207",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-6301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "haNK for Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "avelumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "SBRT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2018-03-19",
      "completion_date": "2024-01-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-09-11T17:55:26.324Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03387085"
    },
    {
      "nct_id": "NCT05618925",
      "title": "Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin's Lymphoma Refractory/Relapsed"
      ],
      "interventions": [
        {
          "name": "N803",
          "type": "DRUG"
        },
        {
          "name": "CD19t-haNK suspension",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-08-22",
      "completion_date": "2027-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-11T17:55:26.324Z",
      "location_count": 2,
      "location_summary": "Newport Beach, California • Tyler, Texas",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05618925"
    },
    {
      "nct_id": "NCT03022825",
      "title": "QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "N-803 and BCG",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2017-06-02",
      "completion_date": "2029-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-09-11T17:55:26.324Z",
      "location_count": 28,
      "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03022825"
    },
    {
      "nct_id": "NCT03586869",
      "title": "QUILT-3.080: NANT Pancreatic Cancer Vaccine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Aldoxorubicin HCl",
          "type": "DRUG"
        },
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-021",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-051",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-061",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-4000",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-6207",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-6301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "haNK for infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SBRT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2018-07-17",
      "completion_date": "2019-08-01",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-09-11T17:55:26.324Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03586869"
    },
    {
      "nct_id": "NCT05096663",
      "title": "Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Advanced Lung Non-Small Cell Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cobalamin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Folic Acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nogapendekin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 82,
      "start_date": "2022-03-15",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-11T17:55:26.324Z",
      "location_count": 350,
      "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Arroyo Grande",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096663"
    }
  ]
}